Shire

Shire
Share

Shire

 •  July 9

Berlin, Germany – July 9 2017 - Shire International GmbH has obtained a preliminary injunction in a court of Hamburg, Germany against F. Hoffmann-La Roche Ltd. (Roche) to address incomplete and misleading statements that may impact important issues of patient safety regarding the investigational treatment emicizumab. Under the injunction, Shire...

Shire

 •  April 26

Natpar is the first and only licensed recombinant human parathyroid hormone therapy for chronic hypoparathyroidism Zug, Switzerland - April 26, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the European Commission (EC) has granted Conditional Marketing Authorisation for Natpar (rhPTH[1-84]), the first recombinant human protein...

Shire

 •  March 22

Lexington, Mass. – March 22, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation for recombinant ADAMTS13 (SHP655 - historically known as BAX930) for treatment of acute episodes of hereditary thrombotic thrombocytopenic purpura (hTTP) in patients...

Shire

 •  March 6

Shire data presentations at AAAAI 2017 reinforce the efficacy, safety, and tolerability of CUVITRU for primary immunodeficiency patients Lexington, Mass. – March 6, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in rare diseases and highly specialized conditions, will present data assessing primary immunodeficiency (PI) patient...

Shire

 •  November 16, 2016

CUVITRU, now available in the U.S., expands Shire’s immunoglobulin portfolio of treatment options to meet the unique needs of children and adults living with primary immunodeficiency Lexington, Mass. – November 16, 2016 – Shire plc (LSE: SHP, NASDAQ: SHPG) announces the launch of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution], the...

Shire

 •  November 12, 2016

Data reveals key findings on the tolerability of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] for patients, regardless of treatment infusion volume and rates Lexington, Mass. – November 12, 2016 Shire plc (LSE: SHP, NASDAQ: SHPG) will present additional data supporting the tolerability of CUVITRU [Immune Globulin Subcutaneous...

Shire

 •  November 4, 2016

16 presentations to highlight innovation in hematology, oncology and genetic diseases Lexington, Mass. – November 4, 2016 – Shire plc (LSE: SHP, NASDAQ: SHPG), the leading global biotechnology company focused on serving individuals with rare diseases, announced today the depth and breadth of the data it will be presenting at the 58th American...

Shire

 •  November 4, 2016

Company to discuss strength of its commercial portfolio and robust pipeline in rare diseases and specialized conditions. Hematology and Immunology franchises and select, late-stage clinical programs to be featured Lexington, Mass. – November 04, 2016 – Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that it will host an Investor Day focused on...

Shire

 •  October 27, 2016

Data support progressing with Phase 3 clinical development program Lexington, Mass. – October 27, 2016 –– For U.S. Audiences Only – Shire plc (LSE: SHP, NASDAQ: SHPG) today presented data from a Phase 2 study evaluating maribavir (SHP620), an investigational antiviral agent studied in patients with cytomegalovirus (CMV) infection undergoing...

Shire

 •  October 24, 2016

Spoken word performer communicates plight of adults with ADHD who remain overlooked and unsupported. Zug, Switzerland – October 24, 2016 – To mark ADHD Awareness Month, Shire plc (LSE: SHP, NASDAQ: SHPG) has today launched a powerful spoken word video to communicate the challenges many adults with Attention Deficit/Hyperactivity Disorder (ADHD)...